Skip to main content
Retour
NUVL logo

Nuvalent, Inc.

Qualité des données : 100%
NUVL
NASDAQ Healthcare Biotechnology
96,43 €
▲ 1,66 € (1,75%)
Cap. Boursière : 7,06B
Fourchette du Jour
94,24 € 97,79 €
Fourchette 52 Semaines
55,54 € 113,02 €
Volume
483 457
Moyenne 50J / 200J
102,59 € / 91,47 €
Clôture Précédente
94,77 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E -16,6 0,4
P/B 5,7 2,9
ROE % -36,7 3,8
Net Margin % 3,9
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Objectif de Cours des Analystes

Hold
137,44 € +42.5%
Low: 120,00 € High: 155,00 €
BPA Prévisionnel
-5,56 €
CA Est.
14 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 6,16 €
1,30 € – 12,24 €
1,3 B 5
FY2029 3,26 €
0,69 € – 6,48 €
930 M 10
FY2028 -0,93 €
-4,47 € – 2,94 €
530 M 12

Points Clés

Debt/Equity of 0,00 — conservative balance sheet
Negative free cash flow of -275,21M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-36,70%
ROIC-24,89%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
0,00
Current Ratio15,27
Interest Coverage0,00

Valorisation

P/E Ratio
-16,59
P/B Ratio5,65
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -425,38M
ROE -36,70% ROA -30,11%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -275,21M
ROIC -24,89% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,00 Current Ratio 15,27
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -16,59 P/B Ratio 5,65
P/S Ratio N/A PEG Ratio -0,35
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 7,06B Enterprise Value 6,80B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 0,0 0,0 0,0
Net Income -425,38M -260,76M -126,22M -81,85M -46,34M
EPS (Diluted) -5,85 -3,93 -2,17 -1,65 -2,13
Gross Profit 0,0 0,0 0,0 0,0 0,0
Operating Income -414,31M -280,37M -149,49M -86,11M -45,82M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,41B 1,14B 732,38M 482,46M 293,82M
Total Liabilities 164,37M 71,96M 31,82M 19,48M 8,79M
Shareholders' Equity 1,25B 1,07B 700,56M 462,98M 285,04M
Total Debt 0,0 0,0 0,0 0,0 0,0
Cash & Equivalents 261,75M 145,69M 335,39M 241,81M 68,53M
Current Assets 1,39B 1,13B 726,49M 477,99M 290,63M
Current Liabilities 91,17M 54,02M 31,82M 19,48M 8,79M